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A B S T R A C T
Aim of this study was to investigate the correlation of matrix metalloproteinase-9 (MMP-9) expression with histo-
pathologic and clinical characteristics of laryngeal squamous cell carcinoma, and to assess the role of MMP-9 expression
in patient survival. Study included 196 patients with squamous cell carcinoma of the larynx treated at ENT Department,
Split University Hospital Centre, from January 1, 2000 till December 31, 2009. The level of MMP-9 expression showed a
statistically significant correlation (p<0.001) with the disease histopathologic grade, stage, metastatic potential, recur-
rence potential, and survival. Kaplan-Meier curve yielded a statistically significant survival difference (p<0.001) among
the three patient groups with different levels of MMP-9 expression. The survival curve clearly showed the MMP-9 expres-
sion as a predictor of survival to be significantly (p<0.001) associated with survival. In this study, MMP-9 expression as
a biological marker showed a potential predictive value in laryngeal squamous cell carcinoma.
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Introduction
Matrix metalloproteinases (MMP) are a family of
proteolytic zinc dependent enzymes that play an essen-
tial role in local invasion, and in regional and distal
metastasizing of malignant tumours, breaking down the
basal membrane and extracellular matrix components.
MMP also influence tumour growth and tumour neo-
angiogenesis1–7. Gelatinases are a MMP subgroup that
includes matrix metalloproteinases-9 (MMP-9) or gelati-
nase B. Gelatinases act by degrading denatured collagen,
basal membrane collagen IV in particular3,8–10. MMP ex-
pression has been found to be typically low or absent in
normal cells of adult body8.
Tumour neoangiogenesis, which is important for fur-
ther neoplasm growth, is facilitated by the action of
MMP that stimulate the release of angiogenic factors and
remodelling of tissue adhesiveness. MMP also play a ma-
jor role in distal tumour metastasizing11,12.
The effect of MMP-9 on tumour differentiation and
progression in oral, oesophageal, lung, ovarian, colon
carcinomas, thyroid papillary carcinoma and melanoma
has been investigated by many authors13–23, whereas only
few studies addressed the effect of MMP-9 in squamous
cell carcinoma of the larynx13,24–26.
The aim of the present study was to assess the corre-
lation of MMP-9 expression with histopathologic and
clinical characteristics of laryngeal squamous cell carci-
noma, and to determine the role of MMP-9 expression in
disease prognosis and patient survival.
Materials and Methods
Patients
This study included 196 patients with squamous cell
carcinoma of the larynx treated at University Depart-
ment of ENT, Head and Neck Surgery, Split University
Hospital Centre in Split, Croatia, from January 1, 2000
till December 31, 2009. The median patient age was 65,
range 37–88 years. There were 189 (96.4%) male and
seven (3.6%) female patients.
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Immunohistochemistry
Expression of MMP-9 in tumour cells was determined
by immunohistochemistry (IH), where it is expressed as
the percentage of stained tumour cells in the overall ma-
terial, with the borderline positive value of 10%. Statisti-
cal analysis was performed by c2-test, whereas predictive
value of the potential predictors was assessed by Cox re-
gression analysis, preceded by Kaplan-Meier curve for
analysis of survival. The level of significance was set at
p£0.05 in all tests.
Protocol of histology slides and
immunohistochemistry staining
Tissue for histology analysis was obtained from oper-
ative material, fixed in 4% buffered formalin for 24 h,
paraffin embedded, cut into 3- to 5-micron sections and
stained by the standard hemalaun eosin (HE) method.
Histologic preparations were selected, their paraffin sec-
tions were cut again and prepared for immunohistoche-
mistry. Immunohistochemical study was performed on
formalin fixed, paraffin embedded sections obtained
from tumour specimens using streptavidin-avidin-biotin
technique (DAKO, Glostrup, Denmark) with diamino-
benzidine as chromogen and hematoxylin as counter-
stain. Pre-treatment of deparaffinised tissue sections
with heat-induced epitope retrieval (HIER) is required
using DAKO Target Retrieval Solution, pH 9 (codes
S2368/S2367). HIER: 15 min at boiling point.
After thermal treatment, the buffer and slides were
cooled for 20 min at room temperature and the sections
were rinsed with deionised water. For MMP-9 identifica-
tion, the MMP-9 A0150 antibody (polyclonal rabbit, anti-
human; DAKO, Glostrup, Denmark), 1:75 dilution, 1-h
incubation, was employed according to the staining pro-
cedure recommended.
The level of MMP-9 expression referred to the inten-
sity of tumour cell staining: 0 = no staining; 1 = weak
staining in more than 10%; and 2 = intensive staining in
more than 10%27 (Figures 1 and 2). According to the
manufacturer’s instructions, normal lung tissue served
as positive control.
Statistical analysis
Excel 2010 (MS Office 2010, Microsoft, USA) and
Statistica 10.0 (StatSoft Inc., Tulsa, USA) were used on
data processing and analysis. The c2-test was employed
to assess the association of the potential predictors/vari-
ables (clinical characteristics and histopathologic fea-
tures with MMP-9 expression). Predictive value of the
potential predictors for disease outcome and patient sur-
vival was assessed by Cox regression analysis and sur-
vival analysis (Kaplan-Meier curve). Statistical signifi-
cance of particular tests was determined at the level of
95% (p£0.05).
Results
Out of 196 study patients, MMP-9 expression was
demonstrated in 95 (48.4%) and high MMP-9 expression
in 62 (31.6%) patients. Negative (level 0) MMP-9 expres-
sion was recorded in 101 (51.5%) and positive MMP-9 ex-
pression in 95 (48.4%) patients: level 1 MMP-9 expres-
sion in 33 (16.8%) and level 2 MMP-9 expression in 62
(31.6%) patients (Figure 3).
Table 1 shows correlation of tumour grade, stage, me-
tastasis, relapse and mortality according to the level of
MMP-9 expression. Results showed a statistically signifi-
cant correlation among the study variables (p<0.001).
The higher the tumour grade, the higher was the MMP-9
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Fig. 1. Weak MMP-9 expression in a well-differentiated
squamous cell carcinoma (IH, x200).
Fig. 2. Intensive MMP-9 expression in poorly differentiated































Fig. 3. MMP-9 expression in 196 patients with squamous
cell carcinoma (%).
expression, present in about 85% of patients (N=22).
The same applied to tumour staging, where level 2 of
MMP-9 expression was recorded in 35% (N=29) of stage
III patients and as many as 86.6% (N=31) of stage IV pa-
tients. Level 2 of MMP-9 expression was present in 90%
of patients with metastases and only 7% of those free
from metastases. In addition, level 2 of MMP-9 expres-
sion was significantly more common in patients with re-
lapses (N=57; 83%) versus only 4% of those free from re-
lapse. Significant correlation was also found between
mortality rate and MMP-9 expression, with level 2 of
MMP-9 expression recorded in more than 80% of patients
having died from primary disease.
Kaplan-Meier curve (Figure 4) showed a statistically
significant difference in survival among the three patient
groups divided according to the level of MMP-9 expres-
sion (c2=152.6; p<0.001). Out of 62 patients with level 2
of MMP-9 expression, 57 (92%) patients had died and
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TABLE 1
CORRELATION OF MATRIX METALLOPROTEINASE-9 (MMP-9) EXPRESSION WITH CLINICAL AND HISTOPATHOLOGIC
CHARACTERISTICS OF 196 PATIENTS WITH LARYNGEAL SQUAMOUS CELL CARCINOMA
MMP-9 expression (n, %)
0 1 2 Total p
Grade
I 64 (83.1) 4 (5.2) 9 (11.7) 77 (100)
<0.001II 36 (38.7) 26 (28) 31 (33.3) 93 (100)
III 1 (3.8) 3 (11.5) 22 (84.6) 26 (100)
Stage
I 51 (87.9) 6 (10.3) 1 (1.7) 58 (100)
<0.001
II 14 (73.7) 4 (21.1) 1 (5.3) 19 (100)
III 34 (41) 20 (24.1) 29 (34.9) 83 (100)
IV 2 (5.6) 3 (8.3) 31 (86.1) 36 (100)
Meta
No 100 (73) 28 (20.4) 9 (6.6) 137 (100)
<0.001
Yes 1 (1.7) 5 (8.5) 53 (89.9) 59 (100)
Relapse
No 100 (78.7) 22 (17.3) 5 (3.9) 127 (100)
<0.001
Yes 1 (1.4) 11 (15.9) 57 (82.6) 69 (100)
Censor
Death from primary disease 0 (0) 10 (14.9) 57 (85.1) 67 (100)
<0.001Death from other diseases 31 (77.5) 9 (22.5) 0 (0) 40 (100)
Alive 70 (78.7) 14 (15.7) 5 (5.6) 89 (100)
Total 101 (51.5) 33 (16.8) 62 (31.6) 196 (100)
TABLE 2
REGRESSION ANALYSIS (COX REGRESSION) OF CLINICAL AND HISTOPATHOLOGIC PREDICTORS OF SURVIVAL
DURING THE STUDY PERIOD
B SE Wald p Exp (B)
95.0% CI for Exp(B)
Lower Upper
Stage I 0.6 0.892
Stage II (1) 8.5 39.5 0.04 0.830 4852.963 0.000 1.89E37
Stage III (2) 8.8 39.5 0.05 0.824 6622.129 0.000 2.52E37
Stage IV (3) 8.6 39.5 0.05 0.827 5437.795 0.000 2.07E37
Grade I 0.7 0.719
Grade II (1) –0.3 0.4 0.6 0.447 0.756 0.367 1.55
Grade III (2) –0.1 0.4 0.1 0.724 0.867 0.393 1.91
MMP-9 0 14.2 0.001
MMP-9 1 (1) 10.7 47.8 0.1 0.822 46394.594 0.000 2.30E45
MMP-9 2 (2) 12.2 47.8 0.1 0.798 207880.355 0.000 1.03E46
only five (8%) were alive at the end of the study period.
On the other hand, all patients without MMP-9 expres-
sion were alive at the same time point.
Table 2 shows regression coefficients obtained by re-
gression analysis of clinical and histopathologic survival
predictors during the study period. MMP-9 expression as
a survival predictor showed higher correlation (p=0.001)
with patient survival than either tumour stage or tu-
mour grade.
Discussion and Conclusion
The survival of patients with squamous cell carci-
noma of the larynx has remained unchanged over the
last three decades.28 In the present study, the value of the
biological marker MMP-9 expression as a prognostic fac-
tor of survival was evaluated in a large group of patients
with squamous cell carcinoma of the larynx. MMP-9 ex-
pression was demonstrated in 95 (48.5%) of 196 study pa-
tients, which is consistent with the results reported by
Bogusiewicz et al. and Uloza et al.26,29. In our study,
MMP-9 expression was presented in three levels (0, 1 and
2). Level 0 (negative) MMP-9 expression was recorded in
101 (51.5%) and positive MMP-9 expression in 95 (48.5%)
patients: level 1 in 33 (16.8%) and level 2 in 62 (31.6%)
patients.
The level of MMP-9 expression yielded a statistically
significant correlation (p<0.001) with histopathologic
grade, stage, metastasizing potential, relapsing potential
and patient survival.
Higher MMP-9 expression was determined in cases
with a higher histopathologic grade, higher, i.e. advanced
stage of disease, and those with high relapsing potential.
In their study, Gou et al. pointed to positive correlation of
the increased MMP-9 expression with the stage of disease
and metastasizing potential. These authors also demon-
strated the increased MMP-9 expression to be associated
with a reduced patient survival30. O-Charoenrat et al. re-
port on a significant correlation between the increased
MMP-9 expression and advanced stages of disease, how-
ever, they observed correlation with all squamous cell
carcinomas of the head and neck, not only laryngeal
carcinoma25. Xie et al. found significant correlation be-
tween the increased MMP-9 expression and metasta-
sizing to lymph nodes2. Wittekindt et al. report on a sig-
nificant correlation of MMP-9 expression with histo-
pathologic grade (degree of differentiation), but not with
the stage of disease, metastasizing potential and tumour
relapsing potential31. Liu et al. did not found significant
correlation between MMP-9 expression and clinico-
pathologic characteristics of squamous cell carcinoma
(histologic grade, TNM clinical stage and primary seat of
disease)32.
In our study, Kaplan-Meier curve yielded a statisti-
cally significant survival difference (c2=152.6; p<0.001)
among three patient groups divided according to the
level of MMP-9 expression. In the group of patients with
level 2 MMP-9 expression, 92% of patients had died and
only 8% survived. In contrast, in the group of patients
with level 0 (negative) MMP-9 expression, the rate of sur-
vival was 100%. Regression analysis of clinical and histo-
pathologic survival predictors during the study period in-
dicated the predictor of MMP-9 expression to be more
significantly (p=0.001) associated with survival than tu-
mour grade and tumour stage.
Odds ratio could be extremely high when the proba-
bility of event for one of the groups is very low, as in our
regression model. Similar results have been reported by
Gou et al.; in their study, the higher MMP-9 expression
was associated with shorter patient survival30.
Significant correlation between MMP-9 expression
and overall survival was also recorded by Smilek et al. in
their study population of 217 patients with head and
neck carcinoma33. Thus, the higher the MMP-9 expres-
sion, the poorer is patient survival.
In our study, expression of the biological marker MMP-9
showed a potential predictive value for squamous cell
carcinoma of the larynx. With a relatively large study
population, the results of the present study contribute to
further clarification of MMP-9 as a prognostic biological
marker to predict tumour aggressiveness and consequen-
tially to tailor therapeutic approach accordingly. As cur-
rently there are no reliable markers for laryngeal carci-
noma, we believe that research should be focused on this
potential marker, in order to establish MMP-9 as a bio-
logical marker predicting tumour aggressiveness. The
modality and extent of therapeutic approach could then
be based on the level of MMP-9 expression.
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Fig. 4. Survival curve according to the level of MMP-9 expression
(0, blue color = no staining; 1, red color = weak staining in more
than 10%; 2, green color = intensive staining in more than 10%).
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IZRA@AJNOST MATRIKS METALOPROTEINAZE-9 U BOLESNIKA S PLO^ASTIM
KARCINOMOM GRKLJANA
S A @ E T A K
Cilj ove studije bio je istra`iti povezanost izra`ajnosti matriks metaloproteinaze-9 (MMP-9) s histopatolo{kim i klini-
~kim osobinama plo~astog karcinoma grkljana, te zna~ajnost izra`ajnosti MMP-9 na pre`ivljavanje pacijenata. U stu-
diju je uklju~eno 196 bolesnika s plo~astim karcinomom grkljana lije~enih u ENT odjelu Klini~kog bolni~kog centra
Split u periodu od 1.sije~nja 2000. do 31. prosinca 2009. godine. Dokazali smo statisti~ki zna~ajnu povezanost (p<0,001)
izme|u stupnja izra`ajnosti MMP 9 i atohistolo{kog gradusa, stadija bolesti, sklonosti metastaziranju, sklonosti reci-
diviranju i pre`ivljenja. Kaplan-Meier krivulja pokazuje statisti~ki zna~ajnu razliku (p<0,001) u pre`ivljenju izme|u 3
skupine bolesnika koji imaju razli~iti stupanj izra`ajnosti MMP 9. U krivulji pre`ivljenja vidljivo je da je prediktor
izra`ajnost MMP 9 zna~ajno (p=0,001) povezan s pre`ivljenjem. Izra`ajnost MMP 9 biolo{kog markera u na{oj studiji
pokazala je potencijalnu prediktivnu vrijednost za planocelularne karcinome grkljana.
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